A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Cardio IQ® ASCVD Risk Panel with Score
Test Code92052
CPT Codes
80061
Includes
Cardio IQ® Cholesterol, Total
Cardio IQ® HDL Cholesterol
Cardio IQ® Triglycerides
Cardio IQ® Non-HDL and Calculated Components
Cardio IQ® Direct LDL
Cardio IQ® ASCVD Risk Scores
If Triglyceride is >400 mg/dL, then Direct LDL will be performed at an additional charge (CPT code(s): 83721).
Cardio IQ® HDL Cholesterol
Cardio IQ® Triglycerides
Cardio IQ® Non-HDL and Calculated Components
Cardio IQ® Direct LDL
Cardio IQ® ASCVD Risk Scores
If Triglyceride is >400 mg/dL, then Direct LDL will be performed at an additional charge (CPT code(s): 83721).
Preferred Specimen
2 mL serum
Patient Preparation
If a cholesterol measurement is to be performed along with triglycerides, the patient should be fasting 9-12 hours prior to collection.
The assay manufacturer Beckman Coulter advises: "N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been. . . determined to interfere with assays for. . . cholesterol, uric acid" where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hrs and a third dose of 100 mg/kg administered over 16 hrs.
Minimum Volume
1 mL
Instructions
For risk calculations to be performed, the following patient specific information have to be provided at time of order:
Age: Years
Gender: M (for male) or F (for female)
Race-African American: Y (for yes) or N (for no)
Systolic Blood Pressure: mmHg
Treatment for High Blood Pressure: Y (for yes) or N (for no)
Diabetes Status: Y (for yes) or N (for no)
Smoking Status: Y (for Yes) or N (for no)
Age: Years
Gender: M (for male) or F (for female)
Race-African American: Y (for yes) or N (for no)
Systolic Blood Pressure: mmHg
Treatment for High Blood Pressure: Y (for yes) or N (for no)
Diabetes Status: Y (for yes) or N (for no)
Smoking Status: Y (for Yes) or N (for no)
Transport Container
Transport tube
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 48 hours
Refrigerated: 5 days
Frozen: 28 days
Refrigerated: 5 days
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Moderate to gross icterus
Methodology
Enzymatic • Spectrophotometry (SP)
Reference Range
Total Cholesterol |
Male (mg/dL) |
Female (mg/dL) |
<20 Years | <170 | <170 |
≥20 Years | <200 | <200 |
HDL Cholesterol | ||
<20 Years | >45 | >45 |
≥20 Years | ≥40 | ≥50 |
Triglycerides | ||
≤9 Years | <75 | <75 |
10-19 Years | <90 | <90 |
≥20 Years | <150 | <150 |
LDL-Cholesterol (Calc) | ||
<20 Years | <110 | <110 |
≥20 Years | <100 | <100 |
Cholesterol/HDL Ratio (Calc) | <5.0 | <5.0 |
Non-HDL Cholesterol | ||
<20 Years | <120 | <120 |
≥20 Years | <130 | <130 |
ASCVD Risk Scores | See Laboratory Report |
Clinical Significance
This panel provides the 10-year and lifetime risk of atherosclerotic cardiovascular disease (ASCVD) using lipid results with anthropomorphic data and family history.
The ASCVD risk assessment is recommended in the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.
The ASCVD risk assessment is recommended in the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.
Performing Laboratory
Cleveland HeartLab, Inc |
6701 Carnegie Avenue, Suite 500 |
Cleveland, OH 44103-4623 |
Last Updated: November 6, 2024